NCT05345327View on ClinicalTrials.gov

SGLT2 Inhibitors As First Line Therapy to Prevent Renal Decline in Type 2 Diabetes

PHASE3RecruitingINTERVENTIONAL
Enrollment

994

Participants

Timeline

Start Date

January 1, 2023

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Type 2 Diabetes
Interventions
DRUG

Dapagliflozin

SGLT2 inhibitor

DRUG

Metformin

Metformin

Trial Locations (8)

2042

RECRUITING

The George Institute for Global Health, Sydney

3004

RECRUITING

Monash University, Melbourne

4000

RECRUITING

The George Institute for Global Health, Brisbane

20000

RECRUITING

Kandy National Hospital, Kandy

40000

RECRUITING

Jaffna Teaching Hospital, Jaffna

80000

NOT_YET_RECRUITING

National Hospital - Galle, Galle

00700

RECRUITING

National Hospital of Sri Lanka 1, Colombo

NOT_YET_RECRUITING

National Hospital of Sri Lanka 2, Colombo

All Listed Sponsors
collaborator

The University of New South Wales

OTHER

collaborator

Monash University

OTHER

collaborator

University of Sydney

OTHER

lead

The George Institute

OTHER